Published in Cancer Sci on January 09, 2012
Primary intrahepatic malignant mesothelioma with multiple lymphadenopathies due to non-tuberculous mycobacteria: A case report and review of the literature. Oncol Lett (2013) 0.91
Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy. Int J Clin Oncol (2013) 0.81
Brain metastases in malignant pleural mesothelioma. Clin Exp Metastasis (2015) 0.81
Malignant peritoneal mesothelioma presenting umbilical hernia and Sister Mary Joseph's nodule. World J Gastrointest Endosc (2013) 0.79
Retrospective analysis of large-scale research screening of construction workers for the early diagnosis of mesothelioma. Mol Clin Oncol (2013) 0.79
Environmental carcinogenesis - 100th anniversary of creating cancer. Cancer Sci (2015) 0.77
Clinical significance of soluble CD26 in malignant pleural mesothelioma. PLoS One (2014) 0.77
Perspectives on refractory ceramic fiber (RCF) carcinogenicity: comparisons with other fibers. Inhal Toxicol (2014) 0.75
Malignant peritoneal mesothelioma with lymph node metastasis that originated in the transverse colon. World J Surg Oncol (2014) 0.75
Sarcomatoid Type Primary Pericardial Mesothelioma with a Long-term Survival after the Onset of Cardiac Tamponade. Intern Med (2016) 0.75
Foreign body granuloma mimicking recurrence of malignant pleural mesothelioma. Respir Med Case Rep (2015) 0.75
Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res (2006) 4.72
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A (2012) 2.89
Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001. J Thorac Oncol (2015) 2.12
Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience. J Thorac Oncol (2010) 1.96
Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay. Clin Cancer Res (2006) 1.91
High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras. Cancer Res (2006) 1.84
Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma. Pathol Int (2007) 1.78
Immunological effects of silica and asbestos. Cell Mol Immunol (2007) 1.69
Chronic lung abscess with Pasteurella multocida infection. Intern Med (2005) 1.62
Comparison of six biological markers for the diagnosis of tuberculous pleuritis. Chest (2004) 1.53
Nucleosomal histone kinase-1 phosphorylates H2A Thr 119 during mitosis in the early Drosophila embryo. Genes Dev (2004) 1.49
Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer. Cancer Res (2009) 1.42
Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas. Cancer Res (2007) 1.42
Elevated serum level of sialylated glycoprotein KL-6 predicts a poor prognosis in patients with non-small cell lung cancer treated with gefitinib. Lung Cancer (2007) 1.40
Gene expression profiles of small-cell lung cancers: molecular signatures of lung cancer. Int J Oncol (2006) 1.38
Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin Cancer Res (2005) 1.36
Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells. Lung Cancer (2011) 1.35
CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection. Cancer Immunol Immunother (2010) 1.25
Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. Cancer Res (2005) 1.24
Lymphomas and glioblastomas: differences in the apparent diffusion coefficient evaluated with high b-value diffusion-weighted magnetic resonance imaging at 3T. Eur J Radiol (2010) 1.23
Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer. Int J Cancer (2006) 1.15
Nonparaneoplastic limbic encephalitis with relapsing polychondritis. J Neurol Sci (2004) 1.14
Differential diagnosis of sarcomatoid mesothelioma from true sarcoma and sarcomatoid carcinoma using immunohistochemistry. Pathol Int (2008) 1.13
ADAM8 as a novel serological and histochemical marker for lung cancer. Clin Cancer Res (2004) 1.10
Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group. Cancer J (2005) 1.10
Malignant pleural mesothelioma in parts of Japan in relationship to asbestos exposure. Ind Health (2004) 1.09
The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer. Int J Cancer (2007) 1.09
Value of immunohistochemistry in the differential diagnosis of pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma. Histopathology (2009) 1.09
General rules for clinical and pathological recording of breast cancer 2005. Breast Cancer (2005) 1.08
Integrated analysis of genetic and epigenetic alterations reveals CpG island methylator phenotype associated with distinct clinical characters of lung adenocarcinoma. Carcinogenesis (2012) 1.07
Identification of cancer stem cell markers in human malignant mesothelioma cells. Biochem Biophys Res Commun (2010) 1.07
Role of PROPELLER diffusion-weighted imaging and apparent diffusion coefficient in the evaluation of pituitary adenomas. Eur J Radiol (2010) 1.06
Expression of MUC1, MUC2, MUC5AC, and MUC6 in atypical adenomatous hyperplasia, bronchioloalveolar carcinoma, adenocarcinoma with mixed subtypes, and mucinous bronchioloalveolar carcinoma of the lung. Am J Clin Pathol (2004) 1.06
Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma. Cancer Res (2009) 1.04
Activation of KIF4A as a prognostic biomarker and therapeutic target for lung cancer. Clin Cancer Res (2007) 1.04
A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras. Mol Cancer Ther (2008) 1.04
Epigenetic silencing of microRNA-34b/c plays an important role in the pathogenesis of malignant pleural mesothelioma. Clin Cancer Res (2011) 1.03
Involvement of IL-10 and Bcl-2 in resistance against an asbestos-induced apoptosis of T cells. Apoptosis (2006) 1.02
Treatment and survival analyses of malignant mesothelioma in Japan. Acta Oncol (2012) 1.01
Asbestos-induced cellular and molecular alteration of immunocompetent cells and their relationship with chronic inflammation and carcinogenesis. J Biomed Biotechnol (2012) 1.01
Frequent methylation and oncogenic role of microRNA-34b/c in small-cell lung cancer. Lung Cancer (2011) 1.01
The neuromedin U-growth hormone secretagogue receptor 1b/neurotensin receptor 1 oncogenic signaling pathway as a therapeutic target for lung cancer. Cancer Res (2006) 0.99
Alterations of Fas and Fas-related molecules in patients with silicosis. Exp Biol Med (Maywood) (2006) 0.98
The reversed apical pattern of MUC1 expression is characteristics of invasive micropapillary carcinoma of the breast. Breast Cancer (2006) 0.97
Survival and prognostic factors in malignant pleural mesothelioma: a retrospective study of 314 patients in the west part of Japan. Jpn J Clin Oncol (2010) 0.96
Meningioangiomatosis occurring in a young male without neurofibromatosis: with special reference to its histogenesis and loss of heterozygosity in the NF2 gene region. Am J Surg Pathol (2002) 0.96
Transcriptional profiling of non-small cell lung cancer cells with activating EGFR somatic mutations. PLoS One (2007) 0.95
CD26 overexpression is associated with prolonged survival and enhanced chemosensitivity in malignant pleural mesothelioma. Clin Cancer Res (2012) 0.94
LRRN4 and UPK3B are markers of primary mesothelial cells. PLoS One (2011) 0.93
Reduction of CXC chemokine receptor 3 in an in vitro model of continuous exposure to asbestos in a human T-cell line, MT-2. Am J Respir Cell Mol Biol (2010) 0.93
Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinoma. Cancer Sci (2008) 0.93
Case of clear cell ependymoma of medulla oblongata: clinicopathological and immunohistochemical study with literature review. Pathol Int (2003) 0.93
Reg IV is an independent prognostic factor for relapse in patients with clinically localized prostate cancer. Cancer Sci (2008) 0.93
CT fluoroscopy-guided cutting needle biopsy of focal pure ground-glass opacity lung lesions: diagnostic yield in 83 lesions. Eur J Radiol (2010) 0.93
Co-existent carcinosarcoma and adenoid basal carcinoma of the uterine cervix and correlation with human papillomavirus infection. Int J Gynecol Pathol (2002) 0.92
The prognostic role of pathologic invasive component size, excluding lepidic growth, in stage I lung adenocarcinoma. J Thorac Cardiovasc Surg (2013) 0.92
Methylation of p14(ARF) gene in meningiomas and its correlation to the p53 expression and mutation. Mod Pathol (2004) 0.91
Aberrant methylation of p14(ARF), p15(INK4b) and p16(INK4a) genes and location of the primary site in pulmonary squamous cell carcinoma. Pathol Int (2004) 0.91
Malignant pericardial mesothelioma with response to chemotherapy. J Thorac Oncol (2009) 0.91
Radiofrequency ablation of early breast cancer followed by delayed surgical resection--a promising alternative to breast-conserving surgery. Breast (2011) 0.91
Association between cytokine removal by polymyxin B hemoperfusion and improved pulmonary oxygenation in patients with acute exacerbation of idiopathic pulmonary fibrosis. Cytokine (2012) 0.91
Overexpression of CD26/DPPIV in mesothelioma tissue and mesothelioma cell lines. Oncol Rep (2011) 0.90
Pulmonary edema as a complication of transcatheter embolization of renal angiomyolipoma in a patient with pulmonary lymphangioleiomyomatosis due to tuberous sclerosis complex. J Vasc Interv Radiol (2009) 0.90
Primary choriocarcinoma of the lung. Anticancer Res (2004) 0.90
Is adenosine deaminase in pleural fluid a useful marker for differentiating tuberculosis from lung cancer or mesothelioma in Japan, a country with intermediate incidence of tuberculosis? Acta Med Okayama (2011) 0.89
Decreased CXCR3 expression in CD4+ T cells exposed to asbestos or derived from asbestos-exposed patients. Am J Respir Cell Mol Biol (2011) 0.89
Characterization of SEZ6L2 cell-surface protein as a novel prognostic marker for lung cancer. Cancer Sci (2006) 0.89
Expression of vascular endothelial growth factor-C and its receptor in invasive micropapillary carcinoma of the breast. Pathol Int (2006) 0.88
Frequent p16 inactivation by homozygous deletion or methylation is associated with a poor prognosis in Japanese patients with pleural mesothelioma. Lung Cancer (2008) 0.88
Inverting enantioselectivity of Burkholderia cepacia KWI-56 lipase by combinatorial mutation and high-throughput screening using single-molecule PCR and in vitro expression. J Mol Biol (2003) 0.88